AbCellera Biologics (DE:8QQ)

FRANKFURT:8QQ

8QQ

AbCellera Biologics

RESEARCH TOOLSreports

AbCellera Biologics (8QQ) Price & Analysis

2 Followers

8QQ Stock Chart & Stats

€2.97

-€0.38(-11.28%)

At close: Jan 08 4:00 PM EST

€2.97

-€0.38(-11.28%)

Day’s Range― - ―

52-Week Range€1.70 - €5.78

Previous CloseN/A

Volume0.00

Average Volume (3M)227.00

Market Cap

€927.16M

Enterprise Value€1.06B

Total Cash (Recent Filing)€560.33M

Total Debt (Recent Filing)€143.22M

Price to Earnings (P/E)―

Beta0.95

Next Earnings

May 11, 2026

EPS Estimate

-0.14

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.03

Shares Outstanding303,160,500

10 Day Avg. Volume0

30 Day Avg. Volume227

Financial Highlights & Ratios

PEG Ratio0.64

Price to Book (P/B)0.90

Price to Sales (P/S)13.60

P/FCF Ratio-5.87

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.05

Price Target Upside70.17% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-0.55

Revenue Forecast (FY)€25.30M

Bulls Say, Bears Say

Bulls Say

Manufacturing And Cash RunwayAnalyst highlights that a new cGMP manufacturing facility combined with licensing revenues from a patent settlement strengthens manufacturing control and supports the cash runway for the internal pipeline.

Patient Convenience And SafetyAnalyst notes that ABCL635's once-monthly injectable dosing and low need for liver monitoring could offer a more convenient and safer alternative to existing therapies, which may boost patient adoption.

Strategic ValidationAnalyst views an upcoming Phase 1/2 readout for ABCL635 as a potential validation of the company's strategic shift toward internally developed drug candidates.

Bears Say

Competitive Efficacy HurdleAnalyst cautions that clinical results will be benchmarked against established competing agents, creating a high efficacy hurdle that could pressure the stock if trial outcomes fall short of expectations.

Revenue Visibility RiskAnalyst warns that management expects research fee revenue to decline as the platform narrows focus toward building the internal pipeline, which could reduce near-term revenue visibility.

AbCellera Biologics News

Abcellera Warns Growing Generative AI Use Raises Cybersecurity, Privacy, and Operational Risks

Abcellera Biologics, Inc. (ABCL) has disclosed a new risk, in the Cyber Security category. Abcellera Biologics, Inc. faces...

1M ago

ABCL

AbCellera (ABCL) Earnings Call: Liquidity, Risks, Catalysts

Abcellera Biologics, Inc. (($ABCL)) has held its Q4 earnings call. Read on for the main highlights of the...

1M ago

ABCL

AbCellera reports FY25 EPS (49c) vs. (55c) last year

Reports FY25 revenue $75.1M vs. $28.8M last year. “In 2025, AbCellera (ABCL) successfully delivered on all its corporate...

1M ago

ABCL

Is ABCL a Buy, Before Earnings?

Abcellera Biologics, Inc. (ABCL) is scheduled to report 4th quarter earnings on 02/24/2026, after the market closes. Regarding...

1M ago

ABCL

AbCellera doses first patients in Phase 2 portion of ABCL635 trial

AbCellera (ABCL) announced that the first patients have been dosed in the Phase 2 portion of its ongoing...

3M ago

ABCL

Viking Therapeutics names Neil Aubuchon as Chief Commercial Officer

Viking Therapeutics (VKTX) announced the appointment of Neil Aubuchon as chief commercial officer. Aubuchon brings more than two...

3M ago

ABCL

VKTX

AbCellera Secures Global Settlement and Patent License Deal

AbCellera Biologics ( ($ABCL) ) has shared an announcement. On December 18, 2025, AbCellera Biologics announced a global...

4M ago

ABCL

AbCellera to receive $36M upfront in patent litigation settlement with Bruker

AbCellera (ABCL) announced that it has entered into a settlement and patent license agreement with Bruker Corporation (BRKR),...

4M ago

ABCL

BRKR

Strategic Shift and Promising Antibody Therapeutics Drive Buy Rating for AbCellera Biologics

In a report released yesterday, David Martin PhD from Bloom Burton maintained a Buy rating on AbCellera Biologics,...

5M ago

ABCL

AbCellera Appoints Dr. Stephen Quake to Board

AbCellera Biologics ( ($ABCL) ) has issued an announcement. On November 10, 2025, AbCellera Biologics announced the appointment...

5M ago

ABCL

AbCellera Biologics’ Earnings Call: Key Insights

Abcellera Biologics, Inc. (($ABCL)) has held its Q3 earnings call. Read on for the main highlights of the...

5M ago

ABCL

3 Best Stocks to Buy Now, 11/7/2025, According to Top Analysts

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below...

5M ago

ABCL

BLND

AbCellera downgraded to Market Perform from Outperform at Leerink

Leerink downgraded AbCellera (ABCL) to Market Perform from Outperform with a $4 price target Published first on TheFly...

5M ago

ABCL

AbCellera Biologics Reports Q3 2025 Financial Results

Abcellera Biologics, Inc. ( ($ABCL) ) has released its Q3 earnings. Here is a breakdown of the information...

5M ago

ABCL

8QQ FAQ

What was AbCellera Biologics’s price range in the past 12 months?

AbCellera Biologics lowest stock price was €1.70 and its highest was €5.78 in the past 12 months.

What is AbCellera Biologics’s market cap?

AbCellera Biologics’s market cap is €927.16M.

When is AbCellera Biologics’s upcoming earnings report date?

AbCellera Biologics’s upcoming earnings report date is May 11, 2026 which is in 35 days.

How were AbCellera Biologics’s earnings last quarter?

AbCellera Biologics released its earnings results on Feb 24, 2026. The company reported -€0.026 earnings per share for the quarter, beating the consensus estimate of -€0.116 by €0.09.

Is AbCellera Biologics overvalued?

According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does AbCellera Biologics pay dividends?

AbCellera Biologics does not currently pay dividends.

What is AbCellera Biologics’s EPS estimate?

AbCellera Biologics’s EPS estimate is -0.14.

How many shares outstanding does AbCellera Biologics have?

AbCellera Biologics has 303,160,500 shares outstanding.

What happened to AbCellera Biologics’s price movement after its last earnings report?

AbCellera Biologics reported an EPS of -€0.026 in its last earnings report, beating expectations of -€0.116. Following the earnings report the stock price went down -0.769%.

Which hedge fund is a major shareholder of AbCellera Biologics?

Currently, no hedge funds are holding shares in DE:8QQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

AbCellera Biologics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-14.16%

Trailing 12-Months

Asset Growth

-0.26%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

AbCellera Biologics

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics (8QQ) Earnings & Revenues

Historic Earnings Reports

8QQ Company Deck

8QQ Earnings Call

Q4 2026

0:00 / 0:00

Earnings Call Sentiment|Positive

The call conveyed meaningful progress in AbCellera's strategic transition to a clinical-stage biotech: solid liquidity (~$700M available), completion of platform and manufacturing investments, successful nomination and clinic advancement of multiple internal candidates, and a roadmap of near- and mid-term clinical catalysts (notably ABCL635 Phase II readout in Q3 2026). At the same time, notable risks and near-term challenges were acknowledged: revenue growth in 2025 was materially influenced by a one-time legal settlement, research fee revenues are expected to decline as the company pivots to internal programs, R&D spending and cash burn remain elevated, and lead programs face clinical and class-specific safety uncertainties that could delay value realization. Overall, the positive operational and pipeline milestones and strong liquidity outweigh the near-term financial and clinical risks.View all DE:8QQ earnings summaries

8QQ Revenue Breakdown

93.51% Research fees

3.94% Royalty revenue

2.55% Milestone payments

8QQ Stock 12 Month Forecast

Average Price Target

€5.05

▲(70.17% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","7":"€7","1.75":"€1.75","3.5":"€3.5","5.25":"€5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.05794161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€6.06</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.0540541432,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.05</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.0462792096,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€3.05</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.029,3.2619955084615384,3.494991016923077,3.7279865253846154,3.960982033846154,4.193977542307692,4.426973050769231,4.659968559230769,4.892964067692308,5.125959576153846,5.358955084615385,5.591950593076923,5.824946101538462,{"y":6.05794161,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.029,3.1847733956307693,3.3405467912615383,3.4963201868923077,3.6520935825230767,3.807866978153846,3.9636403737846155,4.1194137694153845,4.2751871650461535,4.430960560676923,4.586733956307692,4.742507351938462,4.898280747569231,{"y":5.0540541432,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.029,3.0303291699692307,3.0316583399384616,3.0329875099076924,3.034316679876923,3.035645849846154,3.036975019815385,3.0383041897846153,3.039633359753846,3.040962529723077,3.0422916996923077,3.0436208696615386,3.0449500396307694,{"y":3.0462792096,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.979,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.209,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.747,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.9,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.591,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.379,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.632,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.104,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.908,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.029,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >